About Equinox Group

Since 1995 Equinox Group has provided consulting services that support biopharmaceutical R&D decision makers. Clients use our analyses to help:

  • set drug discovery targets
  • inform go/no go decisions at each stage of R&D
  • evaluate in-licensing opportunities
  • choose indications for a molecule with several options,
  • prioritize programs for a therapeutic area strategy,
  • assess R&D portfolio choices
  • forecast the revenue outlook for drugs approaching launch

Equinox Group’s unique analytical perspective overcomes the weaknesses of primary research techniques, and provides clients with a rigorous and inexpensive way to:

  1. measure the magnitude of a new drug’s clinical improvement, and
  2. more accurately assess its commercial potential.


cover1These analytical tools provide insights to inform decisions at all stages of R&D. For an introduction to these methods, see the short video: “How good is your drug?

Walter BrooksWalter Brooks is a Partner at Equinox Group. He holds a B.A. in Economics and an M.S. in Policy Analysis from SUNY at Stony Brook. His expertise is R&D decision support, concentrating on biopharmaceuticals since 1988.
David GodolphinDavid Godolphin is a Partner at Equinox Group. He received an A.B. from Harvard College. He focuses on unmet medical need analysis, forecasting, and drug development strategy.
Allan MillerAllan Miller is a Partner at Equinox Group. He received an M.A. and a Ph.D. in Molecular Biology from the University of Cambridge. His focus is on oncology, virology, and patient flow modeling techniques.
Kaycee ChakrapaniKamakshi (Kaycee) Chakrapani received a B.S. in Chemical Engineering from the Institute of Chemical Technology (Formerly UDCT), Mumbai. She also holds a Master’s of Engineering Management degree from the Thayer School of Engineering at Dartmouth College. Her focus is on forecasting, patient flow modeling techniques, and epidemiology.